Publications in collaboration with researchers from Hospital Vall d'Hebron (14)

2023

  1. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results from a Randomized, Open-Label, Phase III Trial

    Journal of Clinical Oncology, Vol. 41, Núm. 11, pp. 2007-2019

  2. Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer

    Thrombosis Research, Vol. 232, pp. 133-137

2022

  1. Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence

    European Journal of Internal Medicine, Vol. 100, pp. 33-45

2021

  1. Early clinical experience with trifluridine/tipiracil for refractory metastatic colorectal cancer: The ros study

    Cancers, Vol. 13, Núm. 18

  2. Motixafortide and pembrolizumab combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: The COMBAT/ KEYNOTE-202 trial

    Clinical Cancer Research, Vol. 27, Núm. 18, pp. 5020-5027

  3. Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)

    Journal of Clinical Oncology, Vol. 39, Núm. 10, pp. 1108-1118

2020

  1. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

    Nature Medicine, Vol. 26, Núm. 6, pp. 878-885

  2. High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1

    European Journal of Cancer, Vol. 141, pp. 193-198

2019

  1. Management and supportive treatment of frail patients with metastatic pancreatic cancer

    Journal of Geriatric Oncology, Vol. 10, Núm. 3, pp. 398-404

  2. The Ottawa score performs poorly in cancer patients with incidental pulmonary embolism

    Thrombosis Research, Vol. 181, pp. 59-63

  3. Treatment and long-term clinical outcomes of incidental pulmonary embolism in patients with cancer: An international prospective cohort study

    Journal of Clinical Oncology, Vol. 37, Núm. 20, pp. 1713-1720

2018

  1. Management of hyperbilirubinaemia in pancreatic cancer patients

    European Journal of Cancer, Vol. 94, pp. 26-36

2017

  1. Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain

    Clinical and Translational Oncology, Vol. 19, Núm. 6, pp. 667-681

2007

  1. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease

    Haematologica, Vol. 92, Núm. 11, pp. 1489-1494